Because of the associations with BRAF V600E mutations, most clinicians will generally treat thyroid nodules with less common BRAF alterations similarly; however, this may pose a risk of overtreatment if these other nodule genotypes exhibit less aggressive behavior [23]. Here, BRAF is linked to thyroid nodule.